Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 8/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708804 | 0.85 | MAOB (0.46) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL4822863 | 0.81 | MAOB (0.39) | MAOBMAOACDC25B | |
| Hydrochloric Acid SCHEMBL3597821 | 0.79 | MAOB (0.38) | MAOBMAOACDC25B | |
| SCHEMBL15814048 | 0.75 | FABP6 (0.51) | MAOBMAOAPRMT5WDR77 | |
| SCHEMBL8276437 | 0.72 | — | — | |
| Chromanone SCHEMBL29384996 | 0.72 | MAOB (0.56) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| Chromanone SCHEMBL28794 | 0.72 | MAOB (0.56) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| Chromanone SCHEMBL28205525 | 0.72 | MAOB (0.56) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| Chromanone SCHEMBL28719460 | 0.71 | MAOB (0.55) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| Chromanone SCHEMBL28463260 | 0.71 | MAOB (0.55) | MAOBMAOAGRM5NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208056-B2 | Condensed tricyclic compounds as protein kinase inhibitors | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208056-B2 | Condensed tricyclic compounds as protein kinase inhibitors | CDK8, CDK18, CDK2 | MAOB 3068/4885MAOA 3881/4885GRM5 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.